MediciNova, Inc. operates as a biopharmaceutical company. The Company acquires and develops small molecule therapeutics for the treatment of asthma and COPD, progressive multiple sclerosis, neuropathic pain, methamphetamine addiction, interstitial cystitis, and solid tumor cancers. MediciNova offers its products to the healthcare industry with a focus on the Unites States market.

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MediciNova (MNOV US)

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

S-1 | IPO Registration

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-06-17)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)